VAIRES SUR MARNE
Dr Casimir is an expert in organic and medicinal chemistry. Briefly, he obtained his PhD from the Claude Bernard University (Lyon, France, 1997) after three years of intensive research devoted to the design and synthesis of constrained and pseudopeptidic analogues of the HEL(52-61) antigen for evaluation in the treatment of autoimmune diseases. He then performed one year of post-doctoral research at the Free University of Brussels (Belgium) before joining the pharmaceutical and biotechnology industry in France. More especially, in 2002, he joined Theraptosis SA (Paris) where he set up and managed the medicinal chemistry research laboratory. His research projects, mostly focussed on the mitochondrial control of apoptosis, consisted of the development of new peptides and pseudopeptides for evaluation in the treatment of various cancers and of enzyme inhibitors for the treatment of neurological disorders. One of the compounds he co-developed (a peptide-based selective caspase-2 inhibitor called TRP601) was positively adopted by the European Medicinal Agency (EMEA) for treatment of neonatal brain injury in 2006 (the Phase I clinical trials of TRP601 was scheduled for 2008).
Dr Casimir has also a great interest for the strategic and managerial aspects of business. In May 2007, he obtained his MBA in International Business from the Schiller International University (incorporated in the State of Florida, USA) and, in May 2009, he attained the Project Management Professional certification (PMP) from the Project Management Institute (PMI, USA).
Mes compétences :
Biotechnology
Chemistry
Chercheur
Chimie
Création
Gestion Projet
Management
MBA
Medicinal Chemistry
Microsoft Project
Microsoft Project Management
peptide
PMP
Synthèse
Synthèse organique
Synthesis
